<html><body><h2>Case: 1943308</h2><h3> CDS Time: 1987-09-15</h3>
<patient name=1943308>
87.0 year old White_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">87</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">86</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">100</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Chloride</td><td width="200">103.0</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">44</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">61</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">B 12</td><td width="200">217.0</td><td width="200">1984-7-13</td></tr>
<tr><td width="200">Weight</td><td width="200">140</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">HbA1C</td><td width="200">11</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">236</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Urine_ALB/CREAT_RATIO_spot</td><td width="200">25</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Urine_Alb/creat_Ratio_24h</td><td width="200">25</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">173</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">SGOT</td><td width="200">51</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">149</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Height</td><td width="200">65</td><td width="200">1987-7-25</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">173</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">BUN</td><td width="200">29</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">HCT</td><td width="200">44</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">HGB</td><td width="200">15</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Sodium</td><td width="200">136</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">Albumen</td><td width="200">3</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.8</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">UrineAlbumin_24H</td><td width="200">28</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">11</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">UrineAlbumin_SPOT</td><td width="200">28</td><td width="200">1985-1-12</td></tr>
<tr><td width="200">Pulse</td><td width="200">80</td><td width="200">1987-9-15</td></tr>
<tr><td width="200">PLT</td><td width="200">221</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">WBC</td><td width="200">9</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">eGFR</td><td width="200">28</td><td width="200">1987-3-4</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1987-5-3</td></tr>
<tr><td width="200">SGPT</td><td width="200">41</td><td width="200">1987-1-18</td></tr>
<tr><td width="200">Pacemaker</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">PVD</td><td width="200"></td><td width="200">1987-2-15</td></tr>
<tr><td width="200">Sinoatrial node dysfunction</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1987-2-15</td></tr>
<tr><td width="200">Liver_Disease</td><td width="200"></td><td width="200">1987-8-5</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1987-5-3</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">Atrial_Fibrillation</td><td width="200"></td><td width="200">1987-8-22</td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
<tr><td width="200">Race</td><td width="200">White_Non-Hispanic</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> glyburide(10.0) aspirin(325.0) metformin(0.0) amiodarone(200.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Sinoatrial node dysfunction</td>
<td width="200">1987-08-22</td>
<td width="200"> Sinoatrial node dysfunction()</td></tr>
<tr><td width="200">CRI</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(1.8/1987-3-4) && Sex(Female) && Creatinine(1.8/1987-3-4)]()</td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[Treatment_Systolic_BP(149/null) && Treatment_Diastolic_BP(61/null)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Isolated_Systolic_Hypertension K >=3.5</td>
<td width="200"></td>
<td width="200"> Isolated Systolic Hypertension[presence of isolated systolic hypertension && Potassium(4.6/1987-3-4)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[Triglycerides(236.0/1987-1-18)]()</td></tr>
<tr><td width="200">On Amiodarone</td>
<td width="200"></td>
<td width="200"> Amiodarone[amiodarone]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">MI (BP not controlled)</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction[BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">DM and BP not controlled</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of DM && BP not adequately controlled based on most recent BPTreatment_Systolic_BP(149/null)]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(87.0/1970-1-1)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(28.0/1987-3-4)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(28.0/1987-3-4)]()</td></tr>
<tr><td width="200">No med and K>=3.5</td>
<td width="200"></td>
<td width="200"> 1st line drug for hypertension[Potassium(4.6/1987-3-4) && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(87.0/1970-1-1)]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/1987-3-4) && presence of MI]()</td></tr>
<tr><td width="200">MI no HF</td>
<td width="200"></td>
<td width="200"> MI no HF[Absence of HF && Presence of MI]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]()</td></tr>
<tr><td width="200">Hepatobiliary_Diseases</td>
<td width="200">1987-08-05</td>
<td width="200"> Liver_Disease()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Active Liver Disease[SGOT(51.0/1987-1-18)]()</td></tr>
<tr><td width="200">CCS-7.4</td>
<td width="200">1987-02-15</td>
<td width="200"> PVD()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1987-08-22</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1987-08-22</td>
<td width="200"> Sinoatrial node dysfunction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1987-08-22</td>
<td width="200"> Atrial_Fibrillation()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1987-02-15</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/1987-3-4) && presence of MI]()</td></tr>
<tr><td width="200">Pacemaker</td>
<td width="200">1987-08-22</td>
<td width="200"> Pacemaker()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1987-08-22</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1987-05-03</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(4.6/1987-3-4) && presence of MI]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage B HF
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> failed(Treatment_Systolic_BP(149/null))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> failed(LDL_Cholesterol(100.0/1987-1-18))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)
<li>In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li>Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
<li>Patients who have not developed HF symptoms should be treated according to contemporary guidelines after an acute MI. (Level of Evidence: C).
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>Hypertension control <font color=FF0000>preferred</font></b>(rule in criterion<i> BP not under control</i> evaluate to <b> true</b> because <i>BP not under controlTreatment_Systolic_BP(149/null)</i>)])
In patients at high risk for developing HF, systolic and diastolic hypertension should be controlled in accordance with contemporary
guidelines. (Level of Evidence: A)
<li><b>Lipid disorder control <font color=FF0000>preferred</font></b>(rule in criterion<i> Lipid not under control</i> evaluate to <b> true</b> because <i>Lipid not under controlLDL_Cholesterol(100.0/1987-1-18)</i>)])
In patients at high risk for developing HF, lipid disorders should
be treated in accordance with contemporary guidelines. (Level of
Evidence: A)
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>Ventricular rate/sinus rhythm  control <font color=FF0000>preferred</font></b>(rule in criterion<i> Presence of supraventricular tachyarrhythmias</i> evaluate to <b> true</b> because <i>Presence of supraventricular tachyarrhythmias</i>)])
Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b>Secondary prevention</b><br>
<ul>
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
Patients who have not developed HF symptoms should be treated according to contemporary guidelines after an acute MI. (Level of Evidence: C).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>Ace_Inhibitor(Captopril, Lisinopril)<ul><li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>rec add ace: dose adjustent based on kidney functio(Refer to specific ACE Inhibitor dose adjustments based on kidney function.)<li>monitoring renal function and K(Need to find content)<li>preference: preferred</ul><li>Beta blocker stage B post MI(Carvedilol)<ul><li><font color=FF0000>Compelling indications:  MI no HF(MI no HF[Absence of HF && Presence of MI]) </font><li>preference: preferred</ul><li>ARB<ul><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>preference: preferred</ul><li>digoxin<ul><li>preference: neutral<li>No comment</ul><li>Beta Blocker Stage B no MI<ul><li>preference: neutral<li>No comment</ul><li>NDHP CCB<ul><li>Contraindications:  Myocardial_Infarction(Myocardial_Infarction) <li>preference: ruled out</ul></ul></body></html>